Participants 21 125 6
single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder.
Participants 430 610 7
double-blind, placebo-controlled trial of a single intravenous dose of synthetic human secretin in 60 children (age, 3 to 14 years) with autism or pervasive developmental disorder.
Participants 1023 1143 3
Of the 60 children, 4 could not be evaluated - 2 received secretin outside the study, and 2 did not return for follow-up
Participants 1151 1201 4
56 children (28 in each group) completed the study
Participants 1787 1807 3
None of the children
